Korean J Med > Volume 75(3); 2008 > Article
The Korean Journal of Medicine 2008;75(3):815-818.
A anaphylactic reaction to oxaliplatin
Jong Dai Kim, Jeong Ho Lee, Hyun Woong Park, Ki Hong Kim, Mi Il Kang, Do Yeun Cho
증례 : Oxaliplatin에 대한 아나필락시스반응 1예
김종대.이정호.박현웅.김기홍.강미일.조도연, Jeong Ho Lee, Hyun Woong Park, Ki Hong Kim, Mi Il Kang, Do Yeun Cho
Abstract
Oxaliplatin is a third-generation platinum derivative that is used as a first-line regimen in metastatic colorectal cancer. Like other platinum compounds, oxaliplatin can cause hypersensitivity reactions. Since its introduction in late 1990, its use has increased. Hypersensitivity reactions to oxaliplatin are usually mild, and severe hypersensitivity reactions like anaphylaxis are rare. Here, we present an anaphylactic reaction to oxaliplatin in a 63-year-old man with metastatic colon cancer. He was previously treated with a ninth cycle of oxaliplatin plus fluorouracil plus leucovorin (FOLFOX) as first-line palliative chemotherapy, without a hypersensitivity reaction. During the third cycle of fourth-line palliative chemotherapy with bevacizumab, oxaliplatin, fluorouracil, and leucovorin (BV FOLFOX), he complained of feeling warm and diaphoresis, and his blood pressure was 140/90 mmHg. After slowing the oxaliplatin infusion rate, he was given intravenous steroid and antihistamine. He recovered shortly after. During the fourth cycle of chemotherapy, he complained of diaphoresis, chest discomfort, and dyspnea during the oxaliplatin infusion. His blood pressure was 90/60 mmHg. One case of an anaphylactic reaction to oxaliplatin has been reported in Korea. Here, we report an anaphylactic reaction to oxaliplatin with a brief review of the literature. (Korean J Med 75:S815-S818, 2008)
Key Words: Oxaliplatin; Anaphylaxis, Hypersensitivity


TOOLS
METRICS Graph View
  • 948 View
  • 10 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2024 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next